Similar to the reported effectiveness of statins in inhibiting the progression of LNCaP tumours to CRPC state (Wang et al, 2014), we show that decreasing cholesterol bioavailability using statin treatment sensitised SPRY2‐deficient tumours to ADT. The gene discussed is SPRY2; the disease is neoplasm.